For the quarter ending 2025-12-31, DOCS had -$104,411K decrease in cash & cash equivalents over the period.
| Cash Flow | 2025-12-31 | 2025-09-30 | 2025-06-30 |
|---|---|---|---|
| Net income | 61,558 | 62,059 | 53,320 |
| Depreciation and amortization | 3,989 | 3,469 | 2,794 |
| Deferred income taxes | 0 | 0 | - |
| Stock-based compensation, net of amounts capitalized | 33,546 | 29,474 | 21,865 |
| Non-cash lease expense | 459 | 454 | 450 |
| Accretion of discount on marketable securities, net | 1,764 | 2,199 | 2,488 |
| Amortization of deferred contract costs | 2,499 | 2,876 | 3,896 |
| Impairment of long-lived assets | 0 | 0 | - |
| Other | -295 | -294 | 408 |
| Accounts receivable | 27,614 | -12,396 | 13,381 |
| Prepaid expenses and other assets | 12,828 | -7,685 | 4,234 |
| Deferred contract costs | 6,710 | 2,584 | 1,965 |
| Accounts payable, accrued expenses and other liabilities | 41,855 | -2,168 | -165 |
| Deferred revenue | -33,816 | -17,241 | 2,973 |
| Operating lease liabilities | -578 | -571 | -556 |
| Net cash provided by operating activities | 60,891 | 93,944 | 62,101 |
| Cash paid for acquisition, net of cash acquired | 0 | 26,528 | - |
| Purchases of intangible assets | 62 | - | - |
| Internal-use software development costs | 2,313 | 2,369 | 1,966 |
| Purchases of marketable securities | 112,922 | 128,266 | 139,934 |
| Maturities of marketable securities | 143,136 | 125,452 | 144,579 |
| Sales of marketable securities | 10,386 | 0 | - |
| Net cash provided by (used in) investing activities | 38,225 | -31,711 | 2,679 |
| Proceeds from issuance of common stock upon exercise of stock options and common stock warrants | 2,221 | 2,398 | 2,398 |
| Proceeds from issuance of common stock in connection with the employee stock purchase plan | 0 | 1,816 | - |
| Taxes paid related to net share settlement of equity awards | 8,869 | 12,566 | 11,927 |
| Repurchase of common stock | 196,879 | 21,893 | 122,355 |
| Payment of contingent consideration related to a business combination | 0 | 0 | 5,249 |
| Payment of excise taxes on share repurchases | 0 | - | - |
| Net cash used in financing activities | -203,527 | -30,245 | -137,133 |
| Net increase (decrease) in cash and cash equivalents | -104,411 | 31,988 | -72,353 |
| Cash and cash equivalents at beginning of period | 169,249 | 209,614 | - |
| Cash and cash equivalents at end of period | 64,838 | 169,249 | - |
Doximity, Inc. (DOCS)
Doximity, Inc. (DOCS)